Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Rare Bleeding Disorders Home
    • Products
      Our Treatments How to Order Trial Prescriptions Recombinant Manufacturing
    • Professional Resources
      Product Resources Library Contact Your Representative
    • Disease Education
      Clinical Education Library Congenital Hemophilia with Inhibitors Acquired Hemophilia Glanzmann's Thrombasthenia Interactive Joint Bleed Model
    • Treatment Guidelines
      MASAC Guidelines WFH Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Materials
    • Disease Education
      Disease Education Resources
    • Access & Affordability
      Prescription Savings & Insurance Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Acquired Hemophilia
Acquired Hemophilia
  • Overview
  • Diagnosing
  • Clinical Pathway

Acquired hemophilia is a rare condition that appears spontaneously

Actor portrayal

Acquired hemophilia is a rare condition that appears spontaneously

Actor portrayal

rare andspontaneous

In acquired hemophilia, antibodies or inhibitors develop against the body’s own coagulation factor, frequently factor FVIII. Acquired hemophilia (AH) appears spontaneously in people who were not born with hemophilia. Patients may have underlying conditions, but often do not.1-3

Acquired hemophilia is:

Extremely rare— affecting only 1.5 per million people annually4

People icon

Challenging to diagnose—nearly 52% of cases are idiopathic3

Group icon

Potentially fatal—up to 21% mortality rate5

Warning icon

Diagnosis time matters

Acquired hemophilia can be fatal. Knowing how to spot the signs and symptoms is vital, so that critical laboratory tests can be performed and a diagnosis can be made.

Diagnosis time matters

Acquired hemophilia can be fatal. Knowing how to spot the signs and symptoms is vital, so that critical laboratory tests can be performed and a diagnosis can be made.

Infographic stating 35% of patients go undiagnosed for more then 7 days [Reference 3]
Infographic stating 70% of patients experience severe or life-threatening bleeding [Reference 3]

What makes acquired hemophilia difficult to diagnose?

Acquired hemophilia is extremely rare, so many health care providers may have never diagnosed a patient with AH. Patients may present with a variety of underlying conditions (or none at all); in addition, AH is associated with a bimodal age distribution.3

Actor portrayal

AH patients with an underlying condition3

AH patients with underlying conditions percentages

AH patients by underlying condition3,a

AH patients by underlying conditions percentages

aSome patients may have more than one associated disease.
Adapted with permission from Knoebl et al.3

Age and sex distribution of patients with acquired hemophilia3

Median age for AH patients by gender
Median age for AH patients by gender

Adapted with permission from Knoebl et al.3

Review the signs of acquired hemophilia

See the common signs and symptoms of acquired hemophilia, and how patients typically present with this rare bleeding disorder.

Learn about diagnosing AH

Actor portrayal

Explore acquired hemophilia education

Watch videos and listen to presentations covering clinical features, diagnosis and treatment of acquired hemophilia.

Review materials

References:

  1. Tiede A, Collins P, Knoebl P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020;105(7):1-16.
  2. National Hemophilia Foundation. MASAC recommendations concerning products licensed for the treatment of hemophilia and other bleeding disorders, #263. New York, NY: National Hemophilia Foundation; 2020.
  3. Knoebl P, Marco P, Baudo F, et al; EACH2 Registry Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012;10(4):622-631.
  4. Kruse-Jarres R, Kempton C, Baudo F et al. Acquired hemophilia A: Updated review of evidence and treatment guidance. Am J Hematol. 2017;92:695–705
  5. Bitting RL, Bent S, Li Y, Kohlwes J. The prognosis and treatment of acquired hemophilia: a systematic review and meta-analysis. Blood Coagul Fibrinolysis. 2009;20(7):517-523.

 

Rare Bleeding Disorders
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Rare Bleeding Disorders Home
  • Product Information
    Products
    • Our Treatments
      How to Order
      Trial Prescriptions
      Recombinant Manufacturing
    Professional Resources
    • Product Resources Library
      Contact Your Representative
  • Professional Education
    Disease Education
    • Clinical Education Library
      Congenital Hemophilia with Inhibitors
      Acquired Hemophilia
      Glanzmann's Thrombasthenia
      Interactive Joint Bleed Model
    Treatment Guidelines
    • MASAC Guidelines
      WFH Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Materials
    Disease Education
    • Disease Education Resources
    Access & Affordability
    • Prescription Savings & Insurance Support

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to pro.novonordisk.com.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2021 Novo Nordisk All rights reserved.  US21HCP00068 October 2021

Quick links

Trial prescription programs

Patient access and affordability options

MASAC treatment guidelines

Patient educational materials